Northfield Bancorp (Staten Island, Ny) (NFBK -4.31%), a community bank serving New York and New Jersey, posted its results on July 25, 2025. The company reported GAAP EPS of $0.24, outpacing the analyst estimate of $0.23 (GAAP), and GAAP revenue of $38.9 million, beating GAAP expectations of $36.53 million. These results showed marked improvement over the prior-year quarter, with notable gains in profitability and efficiency. Overall, the quarter was defined by outperforming top-line and bottom-line estimat ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/capricor-therape ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTCQX: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team: h ...

LAS VEGAS, July 25, 2025 /PRNewswire/ -- AMH (NYSE: AMH), a leading large-scale integrated owner, operator, and developer of single-family rental homes, published its 2024 Sustainability Report.The report provides transparency on the company's performance and initiatives to build and operate responsibly, invest in a great workplace, and improve the lives of residents. The report can be viewed and downloaded on the company's website."As the U.S. faces a challenging housing landscape, our mission to expand ac ...

Core Insights - Recognify Life Sciences announced that its Phase 2b clinical trial for inidascamine did not meet its primary endpoint for cognitive improvement in patients with cognitive impairment associated with schizophrenia [1][2] - Despite not achieving statistical significance, inidascamine showed consistent numerical improvements across various cognitive measures, including Symbol Coding and Verbal Learning [2][4] - The drug demonstrated a favorable safety profile, with no significant side effects commonly associated with schizophrenia treatments [3][4] Company Overview - Recognify Life Sciences is a clinical-stage biotech company focused on developing pro-cognitive treatments for mental health and neurodegenerative disorders [10] - The company is a strategic investment of atai Life Sciences, which is also involved in developing psychedelic-based therapies for mental health [11] Clinical Trial Details - The Phase 2b trial enrolled 242 patients across the United States and Europe, evaluating the efficacy, safety, and tolerability of inidascamine over a six-week period [4] - The study's primary endpoint was based on the MCCB neurocognitive composite score, which did not show statistical significance, but secondary and exploratory endpoints are still under analysis [2][4] Future Directions - Recognify Life Sciences plans to present additional results from the study at scientific meetings and will evaluate strategic options for inidascamine based on the complete data set [5][6] - The ongoing analysis aims to identify potential responder populations and mechanistic insights that could guide future development [4][5] Industry Context - Cognitive impairment associated with schizophrenia affects approximately 80% of patients, representing a significant unmet clinical need, as there are currently no effective pharmaceutical treatments approved for this condition [9] - The global prevalence of schizophrenia is over 21 million, with around 2.4 million cases in the United States [9]

Core Viewpoint - Velo3D, Inc. has announced a 1-for-15 reverse stock split of its common stock to prepare for a potential listing on a national securities exchange, with the split expected to take effect on July 28, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 15 shares of common stock into one new share, reducing the outstanding shares from approximately 211,011,238 to about 14,067,416 [3]. - The reverse stock split was approved by Velo3D's stockholders on June 27, 2025, and the final ratio was determined by the board on July 18, 2025 [1][3]. - The CUSIP number for the common stock will change to 92259N 302, and the trading symbol will temporarily change to "VLDXD" for 20 business days [1][2]. Group 2: Impact on Shareholders - Fractional shares will not be issued; instead, stockholders entitled to a fractional share will receive one full share [3]. - The number of authorized shares will remain at 500,000,000, and the par value will stay at $0.00001 per share [2][3]. - Proportional adjustments will be made to the exercise prices of outstanding stock options and warrants, as well as to equity-based awards [3]. Group 3: Company Overview - Velo3D specializes in additive manufacturing technologies for mission-critical metal parts, enabling the production of complex designs previously deemed impossible [6][7]. - The company has developed a fully integrated solution that includes Flow print preparation software, the Sapphire family of printers, and the Assure quality control system, powered by its Intelligent Fusion manufacturing process [7]. - Velo3D has been recognized as one of Fast Company's Most Innovative Companies for 2024 and has partnered with notable companies such as SpaceX and Honeywell [7].

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on August 1, 2025, to discuss the company’s financial results for the second quarter ended June 30, 2025. A news release containing the results will be issued before the open of the U.S. equity markets and will be available on http://ir.silvercrestgroup.com/. Chairman, Chief Executive Officer and President Richard R. Hough III and Chief Fina ...

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States ...

Mohawk Industries (MHK) Q2 2025 Earnings Call July 25, 2025 11:00 AM ET Company ParticipantsJames Brunk - CFOJeffrey Lorberbaum - Chairman & CEOPaul De Cock - President & COOMichael Rehaut - Executive DirectorKeith Hughes - Managing DirectorTrevor Allinson - Director - Equity ResearchPhilip Ng - Managing DirectorStephen Kim - Senior MDKathryn Thompson - Founding Partner & CEOConference Call ParticipantsMike Dahl - MD, Equity Research - Homebuilders & Building Products AnalystSam Reid - AnalystSusan Maklari ...

Mohawk Industries (MHK) Q2 2025 Earnings Call July 25, 2025 11:00 AM ET Speaker0Good day, and welcome to the Mohawk Industries Second Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad.Please note this event is being recorded. I would ...